Matthew Hobbs
Dr. Matthew Hobbs is the Director of Research at Prostate Cancer UK, where he plays a crucial role in advancing research and awareness around prostate cancer. He commented on the promising outcomes of the NeuroSafe procedure, which aims to reduce erectile dysfunction in men undergoing prostate cancer surgery. Hobbs emphasizes the need for further research to ensure that innovative surgical techniques can be effectively implemented across the NHS for wider patient benefit.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United Kingdom | 1 | 9.00 | 0.04% | +0% | 67,886,011 | 28,286 | $2,700,000 | 1,125$ |
| Totals | 1 | 67,886,011 | 28,286 | $2,700,000 | 1,125$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United Kingdom:
Dr Matthew Hobbs described the AI test as 'exciting' and supported the call for abiraterone to be made available to men whose lives it can save.
9
United Kingdom:
Dr Matthew Hobbs, the director of research at Prostate Cancer UK, highlighted the importance of innovative surgery techniques in reducing erectile dysfunction.
8